India Pharma Outlook Team | Thursday, 22 October 2026
Roche Q3 CEETRIS growth keeps India at the forefront of the company’s international strategy.
While global observers note the Group’s solid 7 percent constant-exchange-rate rise, the sharper signal for Indian stakeholders arrives from the International region’s 10 percent CER advance.
That zone explicitly includes the Indian subcontinent and continues to rank among Roche’s clearer growth engines outside the United States and Europe.
Strong demand for key specialty brands reinforces India’s position as a strategic priority at a moment when specialty medicine competition intensifies at home.
Roche reported third-quarter group sales of 16.13 billion Swiss francs, up 7 percent at constant exchange rates and 8 percent in Swiss francs. For the first nine months, Group sales reached 46.5 billion francs, a 6 percent CER increase.
The Pharmaceuticals Division delivered 7 percent CER growth over nine months. Top contributors included:
The International region, which covers Asia-Pacific, CEETRIS (Central Eastern Europe, Turkiye, Russia and the Indian subcontinent), Latin America and other markets, advanced 10 percent at CER.
Diagnostics sales rose 4 percent CER over nine months and 5 percent in the third quarter, supported by core laboratory and pathology demand. CEETRIS remains one of the more consistent growth engines outside the major developed markets.
Also Read: India's Role in Shaping the Future of Oncology and Immunology
India forms an integral part of the CEETRIS cluster inside Roche’s International region. The 10 percent CER lift in that region aligns with Roche’s repeated emphasis on faster-growing markets and its dedicated pharmaceuticals and diagnostics footprint in India.
Performance of the key growth brands maps directly onto rising specialty demand across oncology, ophthalmology, haemophilia and multiple sclerosis in the Indian market. Sustained momentum in CEETRIS lowers the risk that India faces reduced priority in global resource allocation. Strong regional results instead strengthen the commercial rationale for continued investment, local partnerships and expanded patient access programs.
Roche states it stands fully prepared to launch giredestrant, its oral breast cancer therapy, later this year and approaches approval of fenebrutinib, an oral multiple-sclerosis treatment. Both assets carry clear relevance for Indian clinicians and patients facing high unmet need in breast cancer and MS.
Solid CEETRIS performance bolsters the case for timely India launches, formulary discussions and broader reach. Regional growth gives Roche additional confidence to prioritize access strategies that match local disease burden and healthcare system readiness.
Roche’s third-quarter update presents steady global progress, yet the CEETRIS numbers quietly confirm that India remains firmly on the priority list. Specialty medicine competition continues to intensify at home, making this regional growth signal especially relevant for Indian stakeholders watching pipeline timing and commercial commitment.
.jpg)
